Roche terminates SCarlet RoAD study of gantenerumab in Alzheimers Disease
Roche has announced the decision to discontinue SCarlet RoAD (WN25203), a phase III study of investigational anti-amyloid medicine gantenerumab in prodromal (pre-dementia) Alzheimer�s disease, based on results of a pre-planned futility analysis and recommendation by the independent Data Monitoring Committee. No new safety signals for gantenerumab were observed in this analysis and the overall safety profile was similar to that seen in the phase I trial (NN19866). Data from the SCarlet RoAD study will be shared with the medical community after full review and analysis.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.